Anti-p53 (mono methyl K372) antibody

The University of Virginia awarded a contract to Epitomics Inc. on August 15, 2026, for the provision of research reagents. The prime contractor, Epitomics Inc., was selected to deliver specialized antibody products to support the institution's research requirements. The contract, identified as A207_PO-0469527, represents a transaction within the Commonwealth of Virginia and carries a cumulative contract value of four hundred dollars.

The specific deliverable under this award consists of one Anti-p53 (mono methyl K372) antibody unit, priced at $400.95 per unit. The antibody is designated for delivery to Max Charles Mendrzycki at the University of Virginia. This line item represents a targeted procurement of a monoclonal antibody targeting a specific post-translational modification of the tumor suppressor protein p53, which is commonly utilized in molecular biology and cancer research applications. The contract terms and conditions, performance timeline, and any renewal provisions are not detailed in the available documentation.